We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellectis Announced Collaboration Agreement with Stemgent
News

Cellectis Announced Collaboration Agreement with Stemgent

Cellectis Announced Collaboration Agreement with Stemgent
News

Cellectis Announced Collaboration Agreement with Stemgent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cellectis Announced Collaboration Agreement with Stemgent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellectis Bioresearch has announced a collaboration agreement with Stemgent, Inc. to provide research services that combines mRNA reprogramming technology and genome engineering.

The partnership marries Cellectis bioresearch’s leadership in genome engineering with Stemgent’s expertise in cellular reprogramming.

Stemgent’s proprietary mRNA reprogramming technology addresses the challenges around deriving non-viral non-integrating clinically-relevant induced pluripotent stem (iPS) cells for use in regenerative medicine drug discovery and basic research.

Traditional reprogramming methods can lead to the integration of unwanted genetic material into the host genome and therefore can be disruptive to the reprogrammed cell’s function.

Targeted genome engineering is a powerful technology that can be used to elucidate the genetic basis of diseases and to evaluate drug candidates through the generation of cell-based assays.

Cellectis bioresearch’s TALEN™-based genome engineering technology enables the directed introduction of disease-specific genetic mutations to mimic disease and of reporter genes with fluorescent/luminescent tags to evaluate drug candidate efficacy specificity and toxicity.

Together these two powerful technologies pave the way for clinically-relevant applications in regenerative medicine.

Cellectis Group CEO André Choulika said “The collaboration between Stemgent and Cellectis fits with our mission to enable scientists worldwide with the tools to generate genome-engineered iPS cells for use in their research and regenerative medicine.”

“Drug toxicity testing is an important part of early-stage drug development continued Ian Ratcliffe Stemgent President and CEO. “The challenge researchers face is that current models to test drugs are often inadequate. With this partnership and the combined technologies we can introduce mutations into reprogrammed cells and differentiate them into downstream lineages. Researchers can utilize these cells to test how mutations known and unknown alter the biology of the cells upon exposure to drugs.”

Advertisement